Dare Bioscience Investor Presentation Deck slide image

Dare Bioscience Investor Presentation Deck

XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2% FDA approved for the treatment of bacterial vaginosis, the most common vaginal condition in women of reproductive age One-time intravaginal administration Commercialization Collaborator: - ORGANON NDA approved December 7, 2021 QIDP, Fast Track and Priority Review Designations XACIATO is indicated for the treatment of bacterial vaginosis in females 12 years and older. See Full Prescribing Information for the safe and effective use of XACIATO. See important safety information on slides 20 and 21. 16
View entire presentation